Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

AARD Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 42.3% from a year ago

Total equity stood at $86.99M at the end of Q1 FY2026, down 42.3% from a year earlier and down 18.4% from the prior quarter.

Context

  • Total equity amounted to 88.2% of total assets at the end of Q1 FY2026, down 7.7 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -42.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$86.99M-18.4% QoQ
Last fiscal yearDec 2025
$106.63M+295.1% YoY
Year agoMar 2025
$150.69M-42.3% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.3%——
1 year+295.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
106.63M USD
Year-over-year change
+295.1%

Total Equity vs competitors

How AARD compares with its peers on the latest reported figures

  • AARD's Mar 2026 total equity of $86.99M is the 8th highest of the 11 companies compared; the peer median is $111.39M.
  • Its year-over-year change of -42.3% is the 8th highest of 11, against a peer median of -17.5%.
  • Total equity amounts to 88.2% of total assets for AARD, versus a peer median of 73.5%.
AARD Competitors Peer median
Total Equity for AARD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZURAZura Bio LimitedMar 2026$216.9M +43.3%—94.9%
ASMBAssembly Biosciences, Inc.Mar 2026$198.61M +632.0%+35.7%84.3%
NAUTNautilus Biotechnology, Inc.Mar 2026$144.42M -25.7%-20.7%81.2%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$136.64M +405.4%+102.0%93.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$116.59M +24.6%-41.4%37.0%
TNYATenaya Therapeutics, Inc.Mar 2026$106.19M -11.1%-20.3%78.6%
CRBUCaribou Biosciences, Inc.Mar 2026$102.02M -53.0%-25.9%68.5%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$86.99M -42.3%—88.2%
AVTXAvalo Therapeutics, Inc.Mar 2026$68.32M -44.3%—68.4%
PYXSPyxis Oncology, Inc.Mar 2026$31.27M -69.7%-30.8%48.6%
FHTXFoghorn Therapeutics Inc.Mar 2026-$76.41M -23.9%—34.4%
Peer median (excluding AARD) $111.39M-17.5%-20.7%73.5%

Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.56M9.74M61.64M47.05M
Short-term Investments546K254K12.02M62.98M
Net Receivables0000
Inventory0000
Other Current Assets70K127K160K1.86M
Total Current Assets16.49M10.37M74.14M111.89M
Property, Plant & Equipment (Net)252K155K735K355K
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets14K13K2.64M4.94M
Total Non-current Assets266K168K3.37M5.3M
Total Assets16.76M10.54M77.51M117.18M
Account Payables259K1.04M2.3M2.07M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities53K45K896K2.91M
Total Current Liabilities595K1.38M4.93M10.55M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities43.92M43.91M126.78M0
Total Non-current Liabilities44.09M43.96M127.22M0
Total Liabilities44.68M45.34M132.15M10.55M
Common Stock0000
Retained Earnings(30.53M)(37.74M)(58.33M)(115.92M)
Accumulated OCI00081K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(27.92M)(34.8M)(54.64M)106.63M
Total Debt262K162K779K441K
Net Debt(15.3M)(9.57M)(60.86M)(46.61M)

Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Intrinsic Alpha fair value

Locked

Current Price

$3.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.